Clinical trial
Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle
NCT00361855 · Neuronyx, Industry · Completed
Key facts
| NCT number | NCT00361855 |
|---|---|
| Title | Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle |
| Official title | A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction |
| Lead sponsor | Neuronyx, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug |
| Interventions | NX-CP105 |
| Enrollment | 18 |
| Start date | Apr 1, 2006 |
| First posted | Aug 9, 2006 |
| Last update posted | Sep 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: